- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Monitoring Myelofibrosis Treatment Response: Guidelines and Considerations
Aaron Gerds, MD, MS, reviews the National Comprehensive Cancer Network (NCCN) guidelines for monitoring myelofibrosis treatment response and delves into crucial aspects like patient impressions, physical examinations, and symptoms.
EP: 1.Myelofibrosis: Characteristics and Subtypes
EP: 2.NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
EP: 3.Understanding Myelofibrosis: Disease Spectrum and Impact on Quality of Life
EP: 4.Prognosis and Treatment Strategies in Myelofibrosis: Risk Assessment and Therapeutic Goals
EP: 5.NCCN Guidelines 2023: Updates in Myelofibrosis Management
EP: 6.NCCN Guidelines: Categories and Recommendations in Myelofibrosis
EP: 7.Integrating Momelotinib: NCCN Guidelines and Drug Comparison
EP: 8.Monitoring Myelofibrosis Treatment Response: Guidelines and Considerations
EP: 9.Future of Myelofibrosis: Anticipated Data and Emerging Therapies
This is a video synopsis/summary of a Guidelines featuring Aaron Gerds, MD, MS.
Gerds clarifies that JAK inhibitors are not contraindicated in anemic patients, highlighting historical usage with ruxolitinib. He emphasizes the challenges of dose reduction, the potential impact on treatment outcomes, and the need for more thoughtful selection among the available JAK inhibitors. Gerds discusses response monitoring, underlining the significance of patient-reported outcomes, especially the patient's global impression of change. He recommends focusing on symptom improvement and palpable spleen length reduction, simplifying evaluation without the need for advanced imaging. The discussion delves into considerations for altering therapy in myelofibrosis, emphasizing the importance of timely assessment, typically within 3 to 6 months. Gerds discusses the RR6 prognostic model (response to ruxolitinib after 6 months), suggesting key questions at these intervals to guide treatment decisions. This segment provides practical insights for clinicians to navigate the nuanced aspects of JAK inhibitor therapy in myelofibrosis.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Taletrectinib Recommended in NCCN Guidelines for ROS1-Positive NSCLC
July 31st 2025Taletrectinib was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a preferred option for the first-line and subsequent treatment of advanced ROS1-positive non–small cell lung cancer (NSCLC).
Read More
Linvoseltamab Added as Preferred Agent in Newest MM Practice Guidelines
July 31st 2025On July 2, linvoseltamab-gcpt (Lynozyfic; Regeneron) received an accelerated approval from the FDA in relapsed/refractory multiple myeloma (MM), and the most recent update to the National Comprehensive Cancer Network guidelines for MM has added the BCMA-targeted bispecific antibody as a preferred treatment option.
Read More
NCCN Guidelines Prioritize Quad Therapy in Multiple Myeloma
November 26th 2024In the most recent update to the National Comprehensive Cancer Network (NCCN) guidelines for treating patients who have multiple myeloma, a quadruplet regimen became the preferred first-line treatment option for transplant-eligible and -ineligible patients.
Read More
